FDA Approval Includes Full ALTUVIIIO™ Pediatric Trial Results
The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for ALTUVIIIO™ (Sanofi) to include the full results of the phase 3 XTEND-Kids clinical trial. ALTUVIIIO is a recombinant factor VIII therapy (rFVIII), developed with proprietary Fc fusion technologies to
Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD
PARAMUS, NJ. 29/04/2024. PRESS RELEASE Octapharma USA, Inc. announced the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, for routine prophylaxis
Upcoming CareFirst Formulary Updates and Medications Added to Prior Authorization List
Carefirst has issued a Medical Preferred Drug Strategy Update effective August 1, 2024. Below is a summary of the factor agents affected. Learn what this means for affected patients.
Study Suggests Prophylaxis Can Mitigate Intracranial Hemorrhage Risk
May 23, 2024 Results of a new study published in the Journal of Blood Medicine (JBM), indicate that people with hemophilia A (HA) who have been on a prophylactic treatment regimen have a reduced risk for intracranial hemorrhage (ICH). Often referred to
Hemophilia Foundation of Maryland (HFM)
13 Class Court Parkville, MD 21234
